TITLE

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

AUTHOR(S)
Vitale, Cristiana; Mercuro, Giuseppe; Castiglioni, Carlotta; Cornoldi, Alessandra; Tulli, Arianna; Fini, Massimo; Volterrani, Maurizio; Rosano, Giuseppe M. C.
PUB. DATE
January 2005
SOURCE
Cardiovascular Diabetology;2005, Vol. 4, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activitygamma (PPARγ) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome. Methods: In a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months. At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour mean systolic and diastolic blood pressures were determined. Results: Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic. Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p < 0.05) and diastolic blood pressure (p < 0.05) compared with losartan. Conclusion: As well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARγ activity.
ACCESSION #
28682790

 

Related Articles

  • ENDOCRINE AND METABOLIC ASPECTS.  // Current Medical Literature: Diabetes;2004, Vol. 21 Issue 1, p9 

    Presents citations and clinician's notes about the endocrine and metabolic aspects of diabetes. Metabolic syndrome as predictor of type 2 diabetes; Association of low plasma ghrelin with insulin resistance, hypertension and the prevalence of type 2 diabetes; Prevalence of delayed gastric...

  • Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. Blázquez-Medela, Ana M.; García-Ortiz, Luis; Gómez-Marcos, Manuel A.; Recio-Rodríguez, José I.; Sánchez-Rodríguez, Angel; López-Novoa, José M.; Martínez-Salgado, Carlos // BMC Medicine;2010, Vol. 8, p86 

    Background: Endoglin is involved in the regulation of endothelial function, but there are no studies concerning its relation with hypertension- and diabetes-associated pathologies. Thus, we studied the relationship between plasma levels of soluble endoglin and cardiovascular alterations...

  • Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cea-Calvo, Luis; Conthe, Pedro; Gómez-Fernández, Pablo; De Alvaro, Fernando; Fernández-Pérez, Cristina // Cardiovascular Diabetology;2006, Vol. 5, p23 

    Background: Target organ damage (mainly cardiac and renal damage) is easy to evaluate in outpatient clinics and offers valuable information about patient's cardiovascular risk. The purpose of this study was to evaluate, using simple methods, the prevalence of cardiac and renal damage and its...

  • Fitness Mitigates Early Metabolic Risks. Shrier, Ian; Cantwell, John D. // Physician & Sportsmedicine;May2004, Vol. 32 Issue 5, p7 

    Low cardiorespiratory fitness places a patient at risk of death, but mechanisms for the association are unclear. According to a study from the Coronary Artery Risk Development in Young Adults (CARDIA) group, poor fitness in young adults is associated with the development of cardiovascular...

  • INFLUENCE OF BETA-BLOCKERS ON INSULIN RESISTANCE IN PATIENTS WITH DIABETES MELLITUS TYPE 2. Damnjanovic, Ivana; Velickovic-Radovanovic, Radmila; Kocic, Radivoj; Zlatkovic-Guberinic�, Sne�ana; Sokolovic, Danka; �indic, Nata�a; Conic, Irena // Acta Medica Medianae;Dec2011, Vol. 50 Issue 4, p23 

    The insulin resistance is present when the concentration of insulin is normal and biological response is decreased. The most frequent metabolic change that was detected during anti-hypertension therapy is a change in the insulin resistance. Beta-blockers are generally accompanied by the...

  • Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Gruber, A.; Horwood, F.; Sithole, J.; Ali, N. J.; Idris, I. // Cardiovascular Diabetology;2006, Vol. 5, p22 

    Obstructive sleep apnoea (OSA) is a cardio-metabolic disorder. Whether metabolic syndrome (MS), insulin resistance (IR) and albuminuria are independently associated with OSA is unclear, but defining the interactions between OSA and various cardiovascular (CV) risk factors independent of obesity...

  • Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) is impaired in monocytes from patients with type I diabetes. Abke, Sabine; Neumeier, Markus; Weigert, Johanna; Wehrwein, Gabriele; Eggenhofer, Elke; Schäffler, Andreas; Maier, Kevin; Aslanidis, Charalampos; Schölmerich, Jürgen; Buechler, Christa // Cardiovascular Diabetology;2006, Vol. 5, p17 

    Background: Systemic adiponectin is reduced in patients with cardiovascular disease (CVD) and low adiponectin may contribute to the pathogenesis of atherosclerosis. However, circulating adiponectin is elevated in type 1 diabetes (T1D) patients, who have also a higher incidence to develop CVD....

  • Trends in hypertension management in Type I diabetes across Europe, 1989/1990 — 1997/1999 S.S. Soedamah-Muthu et al.: Hypertension management in Type I diabetes. Soedamah-Muthu, S. S.; Colhoun, H. M.; Abrahamian, H.; Chan, N. N.; Mangili, R.; Reboldi, G. P.; Fuller, J. H. // Diabetologia;Oct2001, Vol. 45 Issue 10, p1 

    Aims/hypothesis. Our aim was to examine the change in the management of hypertension in patients with Type I (insulin-dependent) diabetes mellitus in Europe, between 1989–1990 and 1997–1999. Methods. Seven-year changes in hypertension treatment and control (defined as blood...

  • Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. Rabi, Doreen M.; Padwal, Raj; Tobe, Sheldon W.; Gilbert, Richard E.; Leiter, Lawrence A.; Quinn, Robert R.; Khan, Nadia // CMAJ: Canadian Medical Association Journal;8/6/2013, Vol. 185 Issue 11, p963 

    The article offers information on the theories of doctors related to the need of appropriate blood pressure targets for patients suffering from hypertension and diabetes. It discusses the possibility of adverse cardiovascular events for patients suffering from both hypertension and diabetes...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics